Oliver Lagore Vanvalin Investment Group Takes Position in Novo Nordisk A/S $NVO

Key Points

• Oliver Lagore Vanvalin Investment Group has made a new investment in Novo Nordisk A/S, acquiring 14,067 shares valued at approximately $977,000.
• Institutional investors currently hold 11.54% of Novo Nordisk A/S's stock, with several hedge funds increasing their stakes significantly in the last quarter.
• Analyst ratings for Novo Nordisk A/S show a mix of upgrades and downgrades, with an average rating of "Hold" and a price target of $81.00.

Oliver Lagore Vanvalin Investment Group bought a new stake in Novo Nordisk A/S (NYSE:NVO - Free Report) during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund bought 14,067 shares of the company's stock, valued at approximately $977,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Acadian Asset Management LLC grew its stake in Novo Nordisk A/S by 15,919.9% in the first quarter. Acadian Asset Management LLC now owns 1,044,658 shares of the company's stock valued at $72,523,000 after purchasing an additional 1,038,137 shares during the last quarter. North Star Investment Management Corp. grew its stake in shares of Novo Nordisk A/S by 18.2% during the first quarter. North Star Investment Management Corp. now owns 20,742 shares of the company's stock worth $1,440,000 after acquiring an additional 3,200 shares during the last quarter. Rhumbline Advisers grew its stake in shares of Novo Nordisk A/S by 10.2% during the first quarter. Rhumbline Advisers now owns 63,539 shares of the company's stock worth $4,412,000 after acquiring an additional 5,898 shares during the last quarter. Eldred Rock Partners LLC grew its stake in shares of Novo Nordisk A/S by 72.0% during the second quarter. Eldred Rock Partners LLC now owns 165,219 shares of the company's stock worth $11,403,000 after acquiring an additional 69,184 shares during the last quarter. Finally, Martin Capital Partners LLC grew its stake in shares of Novo Nordisk A/S by 261.5% during the second quarter. Martin Capital Partners LLC now owns 76,448 shares of the company's stock worth $5,276,000 after acquiring an additional 55,298 shares during the last quarter. Hedge funds and other institutional investors own 11.54% of the company's stock.

Analysts Set New Price Targets

A number of equities research analysts recently commented on the company. BNP Paribas Exane raised Novo Nordisk A/S from an "underperform" rating to a "neutral" rating and set a $54.00 target price for the company in a report on Wednesday, August 13th. HSBC downgraded Novo Nordisk A/S from a "buy" rating to a "hold" rating and set a $57.00 target price for the company. in a report on Thursday, July 31st. Dbs Bank raised Novo Nordisk A/S from a "strong sell" rating to a "hold" rating in a report on Friday, August 22nd. Rothschild & Co Redburn raised Novo Nordisk A/S from a "neutral" rating to a "buy" rating in a report on Tuesday. Finally, Zacks Research downgraded Novo Nordisk A/S from a "hold" rating to a "strong sell" rating in a research note on Wednesday, August 20th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, eleven have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus price target of $81.00.

Novo Nordisk A/S Stock Down 0.6%

Shares of NVO traded down $0.40 during mid-day trading on Friday, reaching $61.45. The company's stock had a trading volume of 12,824,513 shares, compared to its average volume of 13,342,038. Novo Nordisk A/S has a 12-month low of $45.05 and a 12-month high of $129.48. The stock has a market cap of $274.37 billion, a PE ratio of 16.88, a price-to-earnings-growth ratio of 2.33 and a beta of 0.66. The company has a debt-to-equity ratio of 0.52, a current ratio of 0.78 and a quick ratio of 0.56. The company's 50 day moving average is $56.88 and its 200 day moving average is $65.44.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. The company reported $0.97 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.93 by $0.04. The firm had revenue of $11.69 billion for the quarter, compared to the consensus estimate of $77.51 billion. Novo Nordisk A/S had a return on equity of 78.64% and a net margin of 35.60%. Equities analysts anticipate that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Cuts Dividend

The firm also recently declared a semi-annual dividend, which was paid on Tuesday, August 26th. Stockholders of record on Monday, August 18th were issued a $0.4119 dividend. This represents a dividend yield of 240.0%. The ex-dividend date of this dividend was Monday, August 18th. Novo Nordisk A/S's dividend payout ratio (DPR) is currently 22.53%.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.